7.2 Renal Disorders, Dialysis, and Fluid Homeostasis

7.2 Renal Disorders, Dialysis, and Fluid Homeostasis

The kidneys play an indispensable role in maintaining fluid, electrolyte, and acid-base homeostasis, regulating systemic blood pressure, eliminating nitrogenous metabolic wastes, and synthesizing vital endocrine hormones (erythropoietin, renin, and active 1,25-dihydroxyvitamin D3). Impairment of renal function rapidly reverberates across all organ systems. Nurses must possess an advanced understanding of nephrology to identify acute decompensation, manage complex extracorporeal therapies, and implement emergency resuscitation protocols.

---

Acute Kidney Injury (AKI): Etiologies, Biomarkers & Phases

Acute Kidney Injury (AKI) is defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria as an abrupt decline in renal filtration function occurring within 48 hours to 7 days, manifested by an increase in serum creatinine by >= 0.3 mg/dL (>= 26.5 micromol/L) within 48 hours, or a rise in serum creatinine to >= 1.5 times baseline within 7 days, or a documented oliguria of urine volume < 0.5 mL/kg/hr for at least 6 consecutive hours.

Etiological Classification: Prerenal, Intrarenal, and Postrenal AKI

AKI Diagnostic Triad:
1. Prerenal: Hypoperfusion -> Intact Tubules -> High Reabsorption (FeNa < 1%, BUN:Cr > 20:1)
2. Intrarenal: Parenchymal Damage -> Damaged Tubules -> Wasted Solutes (FeNa > 2%, BUN:Cr 10-15:1)
3. Postrenal: Mechanical Outflow Obstruction -> Hydronephrosis on Ultrasound

1. Prerenal AKI (Renal Hypoperfusion)

Prerenal azotemia results from compromised renal perfusion without initial structural or cellular damage to the renal parenchyma. When renal arterial blood flow decreases, the glomerular filtration rate (GFR) drops, triggering autoregulatory compensatory mechanisms (afferent arteriolar dilation mediated by prostaglandins and efferent arteriolar constriction mediated by angiotensin II).

• Common Etiologies: Intravascular volume depletion (severe hemorrhage, gastrointestinal fluid loss, burns, profound dehydration), decreased effective arterial volume (decompensated heart failure, cardiogenic shock, cirrhosis with hepatorenal syndrome), systemic vasodilation (septic shock, anaphylaxis), and pharmacologic disruption of renal hemodynamics (NSAIDs inhibiting afferent vasodilatory prostaglandins; ACE inhibitors/ARBs preventing efferent vasoconstriction).
• Diagnostic Profile: Because tubular cells remain intact and functionally healthy, they maximally reabsorb sodium and water under the influence of aldosterone and antidiuretic hormone (ADH).
  • Fractional Excretion of Sodium (FeNa): < 1% (indicates avid tubular sodium conservation)
  • Urine Sodium Concentration: < 20 mEq/L
  • BUN to Serum Creatinine Ratio: > 20:1 (urea is reabsorbed along with sodium/water; creatinine is not)
  • Urine Specific Gravity & Osmolality: High (> 1.020; urine osmolality > 500 mOsm/kg)
  • Urine Microscopy: Normal or hyaline casts
• Clinical Reversibility: Highly reversible if renal perfusion is promptly restored with IV fluid resuscitation or cardiac inotropic support. If uncorrected, prolonged prerenal ischemia leads to ischemic Acute Tubular Necrosis (intrarenal AKI).

2. Intrarenal / Intrinsic AKI (Direct Parenchymal Damage)

Intrarenal AKI involves direct structural and histological damage to the glomeruli, renal tubules, interstitium, or renal microvasculature. The predominant form encountered in acute hospital settings is Acute Tubular Necrosis (ATN), accounting for nearly 85% of intrinsic cases.

• Common Etiologies:
  • Ischemic ATN: Prolonged, unresolved prerenal shock, severe intraoperative hypotension, sepsis-induced hypoperfusion.
  • Nephrotoxic ATN: Exogenous nephrotoxins including aminoglycoside antibiotics (Gentamicin, Tobramycin, Amikacin—which accumulate in proximal tubular lysosomes), iodinated IV radiocontrast media (causing renal vasoconstriction and direct tubular epithelial cytotoxicity), Vancomycin, Amphotericin B, and chemotherapeutic agents (Cisplatin). Endogenous nephrotoxins include myoglobin released during extensive rhabdomyolysis (crush injuries, statin toxicity, prolonged immobility) and free hemoglobin released during massive intravascular hemolysis.
  • Acute Interstitial Nephritis (AIN): Drug-induced allergic inflammation triggered by penicillins, cephalosporins, sulfonamides, proton pump inhibitors, or NSAIDs, presenting with eosinophilia, fever, and maculopapular rash.
  • Acute Glomerulonephritis: Post-streptococcal glomerulonephritis, lupus nephritis, ANCA-associated vasculitis.
• Diagnostic Profile: Damaged, necrotic tubular epithelial cells lose their reabsorptive and concentrating capacities.
  • Fractional Excretion of Sodium (FeNa): > 2% (inability of necrotic tubules to conserve sodium)
  • Urine Sodium Concentration: > 40 mEq/L
  • BUN to Serum Creatinine Ratio: 10:1 to 15:1 (proportional destruction impairs clearance of both)
  • Urine Specific Gravity & Osmolality: Low and fixed (1.010; osmolality < 350 mOsm/kg, matching plasma isosthenuria)
  • Urine Microscopy: Classic muddy brown granular casts, renal tubular epithelial cells, and epithelial cell casts.

3. Postrenal AKI (Outflow Obstruction)

Postrenal azotemia is caused by mechanical obstruction of the urinary collecting system from the renal pelvis down to the external urethral meatus, generating retrograde hydrostatic back-pressure that impairs glomerular filtration.

• Common Etiologies: Benign prostatic hyperplasia (BPH), prostatic adenocarcinoma, bilateral nephrolithiasis, pelvic malignancies (cervical, colorectal), obstructed or kinked indwelling urinary catheters, and neurogenic bladder.
• Diagnostic Approach: Emergent bedside renal ultrasound to visualize hydronephrosis (pelvicalyceal dilation) and bladder distension.
• Management: Rapid decompression of the urinary system via transurethral or suprapubic catheterization, ureteral stenting, or percutaneous nephrostomy tube placement.

Clinical Phases of Acute Kidney Injury

1. Initiation / Onset Phase: The period between the initial physiological insult (ischemia, nephrotoxin exposure) and the manifestation of tubular injury. Spans hours to days; GFR drops and serum creatinine begins to climb.
2. Oliguric Phase: Characterized by a marked reduction in urine output to < 400 mL/day in adults (or < 0.5 mL/kg/hr), typically lasting 10 to 14 days (longer durations correlate with permanent renal scarring). Key clinical manifestations:
   • Fluid Overload: Peripheral dependent edema, pulmonary crackles, jugular venous distension (JVD), hypertension, and acute pulmonary edema.
   • Metabolic Acidosis: Damaged nephrons cannot synthesize ammonia or excrete hydrogen ions ($H^+$), nor reabsorb bicarbonate, producing a high anion gap metabolic acidosis. Kussmaul respirations develop compensatorily.
   • Electrolyte Abnormalities: Life-threatening hyperkalemia (cardiac arrest risk), hyperphosphatemia, hypocalcemia, and dilutional hyponatremia.
   • Uremic Manifestations: Anorexia, nausea, vomiting, uremic encephalopathy, asterixis, and uremic pericarditis.
3. Diuretic Phase: Renal tubular regeneration begins; glomeruli filter fluid but regenerating tubular epithelium cannot yet concentrate urine or respond to ADH. Urine output increases exponentially, often reaching 3 to 5 liters per day. Nursing priority: Prevent severe hypovolemic dehydration, hypotension, profound hypokalemia, and hyponatremia. Fluid replacement is titrated carefully based on previous hourly urine output.
4. Recovery Phase: GFR increases substantially, serum creatinine and BUN plateau and return toward baseline levels. Complete recovery of tubular function requires 3 to 12 months; some patients develop residual chronic kidney disease.

---

Chronic Kidney Disease (CKD): Staging, Pathophysiology & Medical Management

Chronic Kidney Disease (CKD) represents progressive, irreversible loss of nephron units and renal architecture persisting for >= 3 months. The leading worldwide etiologies are Diabetic Nephropathy (approximately 40% to 45%) and Hypertensive Nephrosclerosis (approximately 25% to 30%), followed by chronic glomerulonephritis and polycystic kidney disease.

CKD Staging by Glomerular Filtration Rate (KDIGO)

Systemic Manifestations & Nursing Interventions

1. Anemia of Chronic Kidney Disease

• Pathophysiology: As functional peritubular capillary interstitial cells in the renal cortex are destroyed by fibrosis, production of erythropoietin (EPO) drops precipitously. Erythropoietin is the master hormone stimulating erythroid progenitor proliferation in the bone marrow. Additional contributing factors include uremic toxins shortening red blood cell lifespan and chronic gastrointestinal blood loss.
• Pharmacotherapy: Administer Erythropoiesis-Stimulating Agents (ESAs) such as Epoetin alfa (50 to 100 units/kg SC or IV 1-3 times weekly) or long-acting Darbepoetin alfa. Co-administer oral or intravenous iron therapy (iron dextran, ferric carboxymaltose) because iron stores are rapidly depleted during accelerated bone marrow erythropoiesis (target serum ferritin > 200 ng/mL and transferrin saturation > 20%).
• CRITICAL BLACK BOX SAFETY LIMIT: ESAs must be titrated conservatively to maintain a target Hemoglobin of 10.0 to 11.5 g/dL. Never target a normal hemoglobin level (> 12.0 to 13.0 g/dL). Clinical trials demonstrate that driving hemoglobin above 12 to 13 g/dL significantly increases the incidence of fatal cardiovascular events, myocardial infarction, stroke, heart failure, and vascular access graft/fistula thrombosis. Furthermore, monitor blood pressure closely; ESAs frequently exacerbate hypertension.

2. CKD Mineral and Bone Disorder (CKD-MBD)

• Pathophysiology: Declining GFR reduces renal phosphate clearance, leading to hyperphosphatemia. Elevated serum phosphorus binds ionized calcium, causing hypocalcemia. Simultaneously, failing renal tubular mass cannot convert 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D3 (Calcitriol) via the 1-alpha-hydroxylase enzyme, severely impairing intestinal calcium absorption. Hypocalcemia and hyperphosphatemia stimulate parathyroid hyperplasia and continuous secretion of Parathyroid Hormone (PTH) (Secondary Hyperparathyroidism). Elevated PTH continuously leaches calcium and phosphorus from skeletal bone matrix, producing osteitis fibrosa cystica, pathological fractures, and widespread metastatic calcification of arterial walls and soft tissues.
• Phosphate Binder Pharmacotherapy: Administer calcium-based binders (Calcium acetate, Calcium carbonate) or non-calcium polymers (Sevelamer carbonate, Lanthanum carbonate).
  • CRITICAL NURSING RULE: Phosphate binders must be administered strictly with meals and snacks (within 15 to 30 minutes of eating). The medication must mix directly with food boluses in the gastrointestinal lumen to bind dietary phosphate into non-absorbable complexes excreted in the feces. If taken on an empty stomach, calcium-based binders are absorbed systemically into the bloodstream, failing to bind food phosphate and causing dangerous hypercalcemia.

3. Strict Dietary Restrictions in Advanced CKD / ESRD

• Sodium: Restricted to 1,500 to 2,000 mg/day (1.5 to 2.0 g/day) to control extracellular volume expansion, edema, and refractory hypertension.
• Potassium: Restricted to 2,000 to 3,000 mg/day (2 to 3 g/day) in advanced CKD and hemodialysis. Teach patients to avoid high-potassium foods: bananas, oranges, cantaloupe, avocados, potatoes, tomatoes, spinach, legumes, and commercial salt substitutes containing potassium chloride.
• Phosphorus: Restricted to 800 to 1,000 mg/day. Avoid dairy products (milk, cheese, yogurt), colas, processed meats containing phosphate preservatives, nuts, and whole grains.
• Fluid Restriction: For oliguric hemodialysis patients, daily fluid allowance is calculated as 500 to 800 mL plus the previous 24-hour urine output. Interdialytic weight gain must not exceed 1.5 to 2.0 kg (or < 3% to 4% of dry weight).
• Protein Regulation:
  • Pre-dialysis CKD (Stages 3 to 4): Moderate protein restriction (0.6 to 0.8 g/kg/day) of high-biological-value protein to minimize nitrogenous waste generation and delay progression.
  • Hemodialysis / Peritoneal Dialysis Patients: Increased protein intake (1.2 to 1.4 g/kg/day) to replenish amino acids lost across dialyzer membranes and peritoneal effluent, preventing uremic sarcopenia.

---

Hemodialysis: Vascular Access, Mechanics & Complications

Hemodialysis (HD) involves diverting blood through an extracorporeal artificial kidney (dialyzer) containing thousands of semipermeable hollow fibers bathed in dialysate solution. Solutes (urea, creatinine, potassium) diffuse down their concentration gradients from blood into dialysate; excess intravascular water is removed across pressure gradients via ultrafiltration.

Arteriovenous (AV) Fistula Creation & Clinical Assessment

AV Fistula Nursing Assessment Protocol:
1. Patency Assessment: Auscultate continuous BRUIT (swishing sound); palpate THRILL (vibration).
2. Absolute Limb Prohibition: NO blood pressures, venipunctures, tight cuffs, or IV lines.
3. Distal Perfusion Check: Assess for Steal Syndrome (cold, pale, painful hand during/after dialysis).

• Surgical Creation: An Arteriovenous (AV) Fistula is the gold-standard permanent vascular access, constructed by direct surgical anastomosis of an artery to an adjacent vein (e.g., radiocephalic fistula [Brescia-Cimino] connecting the radial artery and cephalic vein in the forearm). The direct arterial pressure exposes the vein to high flow (300 to 500 mL/min), causing the vein wall to thicken, dilate, and "arterialize."
• Maturation Timeline: An AV fistula requires 6 to 12 weeks (up to 3 months) to mature before it can withstand repeated cannulation with large-gauge dialysis needles (14- to 16-gauge). (An AV Graft, which utilizes a synthetic PTFE tube bridging an artery and vein, matures in 2 to 4 weeks but carries significantly higher risks of thrombosis and infection).
• Physical Assessment of Patency:
  • Auscultation: The nurse must auscultate over the vascular access with a stethoscope to verify a continuous, low-pitched, swishing vascular murmur termed a Bruit.
  • Palpation: The nurse must lightly palpate over the anastomosis to feel a continuous buzzing or vibratory sensation termed a Thrill.
  • Clinical Significance: The absence of a bruit or thrill indicates acute access thrombosis or occlusion—a medical emergency requiring immediate vascular surgical consultation.
• Steal Syndrome (Arterial Steal Syndrome): Occurs when the low-resistance AV fistula "steals" arterial blood flow from the distal extremity, causing hand ischemia. Assessed by cold, pale, cyanotic distal fingers, diminished radial pulse, paresthesias, and ischemic pain that intensifies during hemodialysis. Severe steal warrants urgent surgical banding or access revision to prevent tissue necrosis.
• STRICT VASCULAR ACCESS EXTREMITY PRECAUTIONS:
  • NEVER measure blood pressure on the extremity with the vascular access.
  • NEVER perform venipuncture, phlebotomy, or intravenous cannulation on the access extremity.
  • Do not allow the patient to wear tight clothing, elastic bandages, wristwatches, or carry heavy bags over the access arm.
  • Place a prominent "Limb Alert" identification band on the patient's affected wrist.

Hemodialysis Mechanics & Dry Weight Concept

• Dry Weight: The patient's prescribed target post-dialysis body weight at which all excess intravascular and interstitial fluid has been removed, the patient is normotensive, and free of peripheral or pulmonary edema. The nurse weighs the patient before and after each session. The difference between the pre-dialysis weight and the dry weight dictates the ultrafiltration goal.
• Medication Administration Timing: Antihypertensive medications (ACE inhibitors, beta-blockers) and dialyzable medications (water-soluble vitamins, aminoglycosides) are held prior to hemodialysis to avoid severe intradialytic hypotension and premature drug clearance.

Dialysis Disequilibrium Syndrome (DDS)

Dialysis Disequilibrium Syndrome is a life-threatening neurological complication occurring during or immediately following hemodialysis, observed predominantly in patients with extremely high initial blood urea nitrogen (BUN > 150 mg/dL) undergoing their first few treatments.

• Pathophysiology: Solutes such as urea are cleared rapidly from the circulating bloodstream by the dialyzer. However, urea clears very slowly across the blood-brain barrier into the cerebral tissue. This differential clearance establishes a hyperosmolar cerebral gradient, drawing water from the vascular space directly into the brain parenchyma, resulting in acute cerebral edema and elevated intracranial pressure.
• Clinical Presentation: Early manifestations include severe headache, restlessness, mental agitation, nausea, and vomiting. Progressive symptoms include muscular twitching, visual disturbances, hypertension, seizures, stupor, and fatal cerebral herniation.
• Nursing Actions: If symptoms develop during dialysis, immediately slow down the blood pump speed or discontinue the hemodialysis session. Administer hypertonic saline or IV mannitol if prescribed to reverse cerebral edema. Prevent DDS by initiating new dialysis patients on short-duration, low-blood-flow treatments (e.g., 2 hours at 150-200 mL/min) daily for several days rather than standard 4-hour high-flux sessions.

---

Peritoneal Dialysis: Catheter Care, Mechanics & Complications

Peritoneal Dialysis (PD) utilizes the patient's rich, semipermeable peritoneal membrane as the filtering surface. A flexible silicone Tenckhoff catheter is surgically implanted into the peritoneal cavity, with double Dacron cuffs anchored into the rectus muscle and subcutaneous tissue to promote fibrous ingrowth and create a barrier against ascending microbial colonization.

The Three-Phase Peritoneal Exchange Cycle

1. Fill / Inflow Phase: 1.5 to 2.5 liters of sterile dialysate solution is infused into the peritoneal cavity via gravity over 10 to 15 minutes. Dialysate formulations contain osmotic dextrose (1.5%, 2.5%, or 4.25% dextrose concentrations). Higher dextrose percentages exert higher osmotic pressure, pulling larger volumes of fluid from peritoneal capillaries (ultrafiltration).
   • CRITICAL TEMPERATURE CONTROL: Dialysate solution must be warmed to physiological body temperature (37°C / 98.6°F) using a dedicated dry heating cabinet or warming plate prior to instillation. NEVER warm dialysate in a microwave oven, which produces unpredictable, localized "hot spots" that cause thermal burns to the peritoneal membrane. Cold dialysate produces intense abdominal cramping, pain, and reflex splanchnic vasoconstriction that impairs solute clearance.
2. Dwell Phase: The fluid remains stationary in the peritoneal cavity for a prescribed dwell time (4 to 8 hours in Continuous Ambulatory Peritoneal Dialysis [CAPD], or shorter cycles overnight in Automated Peritoneal Dialysis [APD]). Diffusion of metabolic wastes and osmotic ultrafiltration occur across peritoneal capillary walls.
3. Drain Phase: The drainage tubing clamp is opened and effluent fluid drains out of the peritoneal cavity by gravity into a drainage collection bag placed below the level of the patient's abdomen over 20 to 30 minutes.

Troubleshooting Sluggish Outflow Drainage

When drain volume is less than expected or outflow slows prematurely:

1. Assess for Mechanical Kinking: Inspect all tubing for kinks, closed clamps, or airlocks.
2. Reposition the Patient: The foremost nursing action is to instruct the patient to turn from side to side or ambulate. Positional shifts allow the internal catheter tip to move away from the peritoneal wall or omental folds, reopening drainage holes.
3. Relieve Constipation: A full, distended sigmoid colon compresses the catheter against the abdominal wall. Bowel regimens (stool softeners, osmotic laxatives) are standard maintenance for PD patients. (Enemas must be used cautiously).
4. Check Drainage Bag Height: Verify that the drainage collection bag is positioned lower than the patient's abdomen to maintain gravity siphon pressure.
5. Assess for Fibrin Clots: Fibrin strands can occlude the catheter lumen. If prescribed, instill low-dose heparin directly into dialysate bags to clear or prevent fibrin plugs.

Peritonitis: The Primary Complication of Peritoneal Dialysis

Peritonitis is the leading cause of technique failure, catheter removal, and hospitalization in PD patients, typically resulting from "touch contamination" during exchange connections (Staphylococcus epidermidis, Staphylococcus aureus) or enteric transmural migration (Escherichia coli).

• Cardinal Clinical Presentation: The earliest, most reliable hallmark is cloudy or turbid peritoneal drainage effluent (normal effluent is completely clear, pale straw-yellow). Accompanied by diffuse abdominal pain, abdominal guarding, rebound tenderness, fever, chills, nausea, and general malaise.
• Diagnostic Confirmation: Effluent peritoneal white blood cell count > 100 cells/microL with >= 50% polymorphonuclear neutrophils (PMNs).
• Nursing Interventions:
  • Send drainage effluent immediately to the laboratory for cell count, differential, Gram stain, and aerobic/anaerobic cultures.
  • Administer prescribed Intraperitoneal (IP) Antibiotics (added directly into the dialysate bags) rather than IV antibiotics, achieving high local bactericidal concentrations in the peritoneal cavity.
  • Maintain strict aseptic technique during all catheter manipulations.

---

Emergency Hyperkalemia Management Protocol

Normal serum potassium ranges from 3.5 to 5.0 mEq/L. Hyperkalemia (serum potassium > 5.0 mEq/L, critical > 6.0 to 6.5 mEq/L) represents the most immediately lethal electrolyte disorder in clinical practice, causing progressive cardiac conduction deceleration, malignant ventricular dysrhythmias, and asystole.

Electrocardiographic (ECG) Progression of Hyperkalemia

ECG Evolution in Progressive Hyperkalemia:
Normal ECG -> Tall, Peaked, Narrow T Waves (K+ 5.5-6.5)
           -> Prolonged PR Interval & Flattened P Waves (K+ 6.5-7.0)
           -> Widened QRS Complex & Conduction Blocks (K+ 7.0-8.0)
           -> Smooth Sine-Wave Pattern -> VFib / Asystole (K+ > 8.0)

1. Mild Hyperkalemia (5.5 to 6.5 mEq/L): Tall, peaked, narrow, symmetrical T waves (tent-shaped) prominent in precordial leads; QT interval shortening.
2. Moderate Hyperkalemia (6.5 to 7.5 mEq/L): Prolongation of the PR interval; flattening and eventual disappearance of P waves; ST-segment depression.
3. Severe / Critical Hyperkalemia (> 7.5 to 8.0 mEq/L): Progressive widening of the QRS complex merging into the T wave, forming a smooth, classic sine-wave configuration; followed immediately by ventricular fibrillation, idioventricular rhythms, or ventricular asystole.

The Three-Tier Emergency Treatment Protocol

Three-Tier Hyperkalemia Protocol:
Tier 1 (Minutes): STABILIZE Myocardium -> IV Calcium Gluconate (10%)
Tier 2 (15-30 Min): SHIFT K+ Intracellularly -> IV Regular Insulin + D50W, Nebulized Albuterol
Tier 3 (Hours): ELIMINATE K+ from Body -> Kayexalate/Patiromer, Loop Diuretics, Hemodialysis

Tier 1: Immediate Myocardial Membrane Stabilization (Acts in 1 to 3 Minutes)

• Medication: IV Calcium Gluconate (10% solution, 10 to 20 mL IV over 2 to 5 minutes) (or IV Calcium Chloride via central access).
• Mechanism: Calcium does NOT lower the serum potassium concentration by even 0.1 mEq/L. Instead, calcium increases the threshold potential of cardiac myocytes, restoring the normal difference between resting membrane potential and threshold potential. This immediately abolishes cardiac excitability disturbances and protects against ventricular fibrillation within 1 to 3 minutes (duration of action 30 to 60 minutes).
• Nursing Rule: Always administer first whenever ECG changes (peaked T waves, wide QRS) or K+ > 6.5 mEq/L are documented.

Tier 2: Rapid Intracellular Potassium Shift (Acts in 15 to 30 Minutes)

These agents temporarily drive potassium from the extracellular fluid compartment into intracellular compartments, lowering serum potassium for 2 to 6 hours while elimination therapies are initiated.

1. IV Regular Insulin with 50% Dextrose (D50W):
   • Administer 10 units of IV Regular Insulin accompanied by 50 mL of 50% Dextrose (25 g dextrose) over 5 minutes. Insulin binds membrane receptors, stimulating the cellular $Na^+/K^+$-ATPase pump to transport potassium into skeletal muscle and hepatic cells. Dextrose prevents severe insulin-induced hypoglycemia. (Check capillary blood glucose every 30 to 60 minutes).
2. Nebulized Beta-2 Adrenergic Agonists (Albuterol):
   • Administer 10 to 20 mg of nebulized Albuterol in 4 mL normal saline over 15 minutes (a dose 4 times higher than standard asthma dosing). Beta-2 receptor stimulation directly activates $Na^+/K^+$-ATPase, shifting potassium intracellularly and lowering serum potassium by 0.5 to 1.0 mEq/L.
3. IV Sodium Bicarbonate (50 mEq IV push):
   • Indicated specifically when hyperkalemia is accompanied by severe metabolic acidosis (pH < 7.20). Elevating systemic pH stimulates $H^+/K^+$ antiporters to drive hydrogen ions out of cells in exchange for potassium entering cells.

Tier 3: Total-Body Potassium Elimination (Definitive Removal)

1. Gastrointestinal Cation Exchangers:
   • Sodium Polystyrene Sulfonate (Kayexalate): Administered orally (15 to 30 g) or as a retention enema. Exchanges sodium ions for potassium ions in the large intestine, eliminating potassium in stool over 2 to 4 hours. CONTRAINDICATION: Never administer to patients with paralytic ileus, bowel obstruction, or recent abdominal surgery; sorbitol-containing formulations can cause extensive intestinal necrosis.
   • Modern Potassium Binders: Patiromer (exchanges calcium for potassium in colon) or Sodium Zirconium Cyclosilicate (SZC / Lokelma) (highly selective inorganic crystal capturing potassium throughout the GI tract, acting within 1 hour).
2. Renal Excretion (Loop Diuretics):
   • Administer IV Furosemide (40 to 80 mg) to promote renal potassium excretion in patients with preserved, responsive kidney function.
3. Emergent Hemodialysis:
   • The ultimate, most definitive, and most rapid method for total-body potassium clearance, clearing 25 to 50 mEq of potassium per hour. Indicated for ESRD patients, refractory hyperkalemia, or patients with acute anuric renal failure.